TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Markers of Bacterial Translocation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Symptom Days
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: maximum torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child urine cotinine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Indices of inflammation in nasal lavage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Graft function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of patients with serious or life-threatening toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Change in vital signs after [131]I-IAZA injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in hematology/SMA-12 serum biochemistry after [131]I-IAZA injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in TSH level after [131]I-IAZA injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Accuracy of 3D printed full arch & segmented transfer tray
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post operative analgesia requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analogue scores
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change in symptoms of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Glucagon-like Peptide 1 secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Crude Cure Rate on Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response (CR) + complete response with incomplete marrow recovery (CRi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Immunosuppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Chronic bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Decreased growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hemodynamic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Level of periodontal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful treatment with diltiazem
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HDSS Success
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Absolute Difference Between Unattended and Attended Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy of Measuring Asleep Blood Pressure Using a Home Blood Pressure Monitor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tolerability of Wearing a Home Blood Pressure Monitor Versus an Ambulatory Blood Pressure Monitor
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: anterior chamber cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total microorganism count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Device Related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Patients With Complete Occlusion of the Left Atrial Appendage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Facilitating Abstinence from Smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal Tolerance Dose (MTD)
Endpoint domain: Adverse events/effects
Primary endpoint: Tumor Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Failed epidural placement rate
Endpoint domain: Adverse events/effects
Primary endpoint: Late loss in lumen diameter in follow-up ≥50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death, non-fatal stroke 30 days after stent implantation
Endpoint domain: Mortality/survival
Primary endpoint: Death, non-fatal stroke 12 months after stent implantation
Endpoint domain: Mortality/survival
Primary endpoint: Change in Cognitive Brief Battery (CBB) score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Postural control response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in SOFA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of sufficient recanalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Predictive value of drains amylase values for Pancreatic Fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Newborn weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with postoperative delirium
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of approached participants who consent to study participation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent of participants who complete all 12 weeks of memantine/placebo therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of participants who complete at least 3 of 4 cognitive assessments
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Total Corneal Fluorescein Staining Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Attachment Loss (CAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in resting state brain networks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Access Site-related Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Access Site-related Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Perforation
Endpoint domain: Adverse events/effects
Primary endpoint: Stent Migration/Dislodement
Endpoint domain: Adverse events/effects
Primary endpoint: Tissue Injury
Endpoint domain: Adverse events/effects
Primary endpoint: SAE's
Endpoint domain: Adverse events/effects
Primary endpoint: IOP <= 18 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IOP <= 15 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IOP >= 20% reduction from untreated baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value of hypoperfusion hypodensity mismatch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of hypoperfusion hypodensity mismatch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Cumulative Days on Anticoagulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of patients with sarcoidosis diagnosed by EBUS-TBNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child externalizing behavior (Intensity Scale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child externalizing behavior (Problem Scale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parenting Skills (DPICS-IV)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parenting Stress (PSI-SF-4)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Family conflict (Bloom's Family Processes Scale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Family cohesion (Bloom's Family Processes Scale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: antiplatelet effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effectiveness of hypomethylating agents (HMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sepsis within 28 days after surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Return of Upper and Lower GI Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Clinical Laboratory Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical efficacy of CC-10004 in psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of allergies (eczema, asthma, allergic rhinitis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of abnormal clinical laboratory test results
Endpoint domain: Adverse events/effects
Primary endpoint: Number of abnormal physical examination findings
Endpoint domain: Adverse events/effects
Primary endpoint: Number of abnormal vital signs findings
Endpoint domain: Adverse events/effects
Primary endpoint: Number of abnormal 12 Lead ECG findings
Endpoint domain: Adverse events/effects
Primary endpoint: Ocular Pain Scores on the Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular Discomfort Scores on the Ocular Surface Disease Index (OSDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbO (Oxyhemoglobin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: HHb (Deoxyhemoglobin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in intrahepatic fat content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Compressive Force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemodynamic measures of brain function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Patients Who Developed Cytomegalovirus (CMV) Disease
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse events and laboratory abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Resolution of Bowel Obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Postoperative Wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Systolic BP diminution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cumulative MACE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of subjects with probing depth ≥ 5 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Jump Step Intervention Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Brain lactate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracranial hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Retained in Study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Client Satisfaction Questionnaire (CSQ) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difficulties in Emotion Regulation Scale (DERS) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Suicide Mortality Rates
Endpoint domain: Mortality/survival
Primary endpoint: Foot Care Behavior Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient Interpretation of Neuropathy (PIN) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Complete Resolution of Anterior Chamber Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in Objective Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life assessed by EQ-5D-3L
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life assessed by MOS-SF-36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: sperm DNA methylation profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in NAFLD Activity Score (NAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day point prevalence abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of days to achieve complete healing of cutaneous lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in pain score using the Zoster Brief Pain Inventory (ZBPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the quality of life score as measured by the Dermatology Life Quality Index (DLQI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Fibroblast Growth Factor-23 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Asthma exacerbations requiring prednisone
Endpoint domain: Adverse events/effects
Primary endpoint: Peak cough flow (PCF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: HOOS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxford knee score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Develop Anti-MOR03087 Antibodies
Endpoint domain: Adverse events/effects
Primary endpoint: mRS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Persistence with aripiprazole once-monthly treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters of GDC-0941
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numerical Rating Scale (NRS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of complications after treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Type of complications after treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change rate in medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Late luminal loss at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: same day discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Healing or non-healing of venous leg ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Deep periodontal pockets (5mm or over)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Premature death
Endpoint domain: Mortality/survival
Primary endpoint: Enjoyment of food consumed
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: immediate decline in ovarian reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: time to onset of menopause
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: time before conception success decreases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Brachytherapy treatment parameters (V150)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: incidence of spine unplanned re-operation
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Oxygen Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: overweight/obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between endoscopy- and histology-determined surveillance strategies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angiographic Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Primary Patency of Cephalic Arch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Application of post-operative ERAS items
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Average Daily Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Worst Daily Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cellular high energy phosphate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in venous pH concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cellular oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum markers of myocellular injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Intensity at Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in oral glucose tolerance test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lymphopenia measured by lymphocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion Days Abstinent
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: treatment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: AUCt of Ticagrelor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Ticagrelor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction of remission in Crohn's Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Administration of Propofol 1% Required to Obtain Uniform Sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Youth risk behaviors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: ∆ADC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ∆TLG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Box and Block test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Action Research Arm Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of stroke, systemic embolism and covert embolic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: In-stent thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Avoidance of unscheduled surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to cessation of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance Walked in 6 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Findings in Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of intraoperative and postoperative adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in maternal weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Developmental assessment using Bayley Scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biopsy changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescue analgesic
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in BNP concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical HF decompensations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Respiratory Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pediatric Anesthesia Emergence Delirium (PAED) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative amount of 14C-BIRB 796 BS radioactivity excreted in feces (percent of dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative amount of 14C-BIRB 796 BS radioactivity excreted in urine (percent of dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum observed Concentration (Cmax) of 14C-BIRB 796BS in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Western Ontario Rotator Cuff Index (WORC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes